Factors affecting warfarin therapy following cardiac valve surgery

被引:19
作者
Lee, J
Lee, B
Kim, K
Ahn, H
Suh, O
Lee, M
Shin, W
机构
[1] Seoul Natl Univ, Coll Pharm, Kwanak Gu, Seoul 151742, South Korea
[2] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul, South Korea
[3] Chungbuk Natl Univ, Coll Pharm, Cheongju, Chungbuk, South Korea
[4] Seoul Natl Univ Hosp, Dept Pharm, Anticoagulat Serv, Seoul 110744, South Korea
[5] Seoul Natl Univ Hosp, Dept Thorac Surg, Seoul 110744, South Korea
关键词
anticoagulation response; cardiac valve; warfarin;
D O I
10.1345/aph.1A431
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To determine the factors that affect the initial response to warfarin therapy in Korean patients after cardiac valve surgery. METHODS: A retrospective analysis of 127 patients who had undergone cardiac valve surgery at Seoul National University Hospital was performed. On the first day, most patients received warfarin 5 mg, while some received an individualized warfarin dose according to their physician's decision. Doses to be given on the following days were determined based on daily international normalized ratio (INR) and the previous doses. To measure warfarin sensitivity, the warfarin dose index (WDI), defined as the INR divided by the mean warfarin dose administered during the preceding 3 days, was introduced. The effects of age, gender, weight, serum albumin concentration, baseline INR, cardiopulmonary bypass time, and concurrent administration of amiodarone were evaluated. RESULTS: The patients' weight, initial serum albumin concentration, and baseline INR value influenced their initial response to warfarin. The initial WDI correlated negatively with the initial serum albumin concentration (p < 0.001) and body weight (p < 0.05) and positively with the baseline INR (p < 0.01). The initial WDI of the patients taking amiodarone was significantly higher (mean SD 0.74 +/- 0.34) than that of patients without amiodarone (0.46 +/- 0.22) (p < 0.001). Maintenance doses correlated negatively with the initial warfarin response (p < 0.001) and positively with body weight (p = 0,053). CONCLUSIONS: The factors associated with an increased initial warfarin response in patients after cardiac valve surgery were high baseline INR, low postoperative serum albumin concentration, and concurrent administration of amiodarone. Thus, patients with any of these factors should receive a smaller initial warfarin dose. Also, to predict the warfarin maintenance dose from the initial response, the effect of transient changes in the sensitivity to warfarin during the initial period should be considered.
引用
收藏
页码:1845 / 1850
页数:6
相关论文
共 27 条
[1]   MECHANISM OF WARFARIN POTENTIATION BY AMIODARONE - DOSE-DEPENDENT AND CONCENTRATION-DEPENDENT INHIBITION OF WARFARIN ELIMINATION [J].
ALMOG, S ;
SHAFRAN, N ;
HALKIN, H ;
WEISS, P ;
FARFEL, Z ;
MARTINOWITZ, U ;
BANK, H .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 28 (03) :257-261
[2]   THE INFLUENCE OF PROPHYLACTIC ANTIBIOTICS ON THE WARFARIN ANTICOAGULATION RESPONSE IN THE POSTOPERATIVE PROSTHETIC CARDIAC-VALVE PATIENT - CEFAMANDOLE VERSUS VANCOMYCIN [J].
ANGARAN, DM ;
DIAS, VC ;
AROM, KV ;
NORTHRUP, WF ;
KERSTEN, TE ;
LINDSAY, WG ;
NICOLOFF, DM .
ANNALS OF SURGERY, 1984, 199 (01) :107-111
[3]   Consensus guidelines for coordinated outpatient oral anticoagulation therapy management [J].
Ansell, JE ;
Buttaro, ML ;
Thomas, IV ;
Knowlton, CH ;
Becker, DM ;
Bussey, HI ;
Corey, R ;
Gums, JG ;
Hughes, R ;
Jacobson, A ;
Kirchain, W ;
Kuhn, K ;
Loken, S ;
McCain, J ;
Haley, JA ;
Oertel, LB ;
Thrasher, K ;
Triplett, DA ;
Whitcomb, H ;
Wittkowsky, AK ;
Zarus, SA .
ANNALS OF PHARMACOTHERAPY, 1997, 31 (05) :604-615
[4]   THROMBOEMBOLIC AND BLEEDING COMPLICATIONS IN PATIENTS WITH MECHANICAL HEART-VALVE PROSTHESES [J].
CANNEGIETER, SC ;
ROSENDAAL, FR ;
BRIET, E .
CIRCULATION, 1994, 89 (02) :635-641
[5]   DEFINED ETCHING OF CARBON-DIAMOND FILMS ON SILICON USING AN OXYGEN PLASMA WITH TITANIUM MASKING [J].
CHAN, KK ;
AMARATUNGA, GAJ ;
WONG, TKS .
DIAMOND AND RELATED MATERIALS, 1992, 1 (2-4) :281-284
[6]  
CHOONARA IA, 1988, BRIT J CLIN PHARMACO, V25, P1
[7]  
ECCLES JT, 1988, AGE AGEING, V17, P401
[8]  
GANEVAL D, 1986, CLIN NEPHROL, V25, P75
[9]  
Gelb AB, 1996, AM J CLIN PATHOL, V106, P87
[10]   Mechanism of action, clinical effectiveness, and optimal therapeutic range [J].
Hirsh, J ;
Dalen, JE ;
Anderson, DR ;
Poller, L ;
Bussey, H ;
Ansell, J ;
Deykin, D ;
Brandt, JT .
CHEST, 1998, 114 (05) :445S-469S